Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Longevity Health Holdings, Inc.CTCX · Entity 8659 | Chief Quality Officer | July 14, 2023 | July 19, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Longevity Health Holdings, Inc.
Report date July 14, 2023 · Filed July 19, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 37,296 |
Reported balance
After 2023-07-14 transaction · row 1
1 source rowRow 1 · 2023-07-14 · Grant · Acquired 37,296 · Balance 37,296 F1: On July 14, 2023, Alpha Healthcare Acquisition Corp. III ("ALPA") consummated a business combination (the "Business Combination") by and among ALPA, Candy Merger Sub, Inc., a Delaware Corporation ("Merger Sub") and Carmell Regen Med Corporation, a Delaware corporation ("Legacy Carmell"), ALPA changed its name to "Carmell Therapeutics Corporation" and Merger Sub merged with and into Legacy Carmell. As part of the Business Combination, each share of common stock of Legacy Carmell was exchanged for 0.06154 shares of common stock of Carmell Therapeutics Corporation. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.79 · Expires 2027-06-20 | Direct | 2,090 |
Reported balance
After 2023-07-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-07-14 · Grant · Acquired 2,090 · Balance 2,090 F7: As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation. F2: Options are fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.27 · Expires 2029-07-19 | Direct | 5,318 |
Reported balance
After 2023-07-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-07-14 · Grant · Acquired 5,318 · Balance 5,318 F7: As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation. F3: Options to purchase 5,318 shares of common stock of Legacy Carmell granted on July 19, 2019, which vest as follows: 25% vested on July 19, 2020, July 19, 2021 and July 19, 2022 and the remaining 25% becomes vested on July 19, 2023. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.11 · Expires 2031-09-23 | Direct | 119,098 |
Reported balance
After 2023-07-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-07-14 · Grant · Acquired 119,098 · Balance 119,098 F7: As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation. F4: Options to purchase 119,098 shares of common stock of Legacy Carmell granted on September 23, 2021, which vest as follows: 25% vested on September 23, 2022 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.11 · Expires 2032-07-13 | Direct | 12,309 |
Reported balance
After 2023-07-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-07-14 · Grant · Acquired 12,309 · Balance 12,309 F7: As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation. F5: Options to purchase 12,309 shares of common stock of Legacy Carmell granted on July 13, 2023 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.60 · Expires 2032-12-15 | Direct | 12,309 |
Reported balance
After 2023-07-14 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-07-14 · Grant · Acquired 12,309 · Balance 12,309 F7: As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation. F6: Options to purchase 12,309 shares of common stock of Legacy Carmell granted on December 15, 2022, which vest as follows: 25% vesting on December 22, 2023 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 14, 2023, Alpha Healthcare Acquisition Corp. III ("ALPA") consummated a business combination (the "Business Combination") by and among ALPA, Candy Merger Sub, Inc., a Delaware Corporation ("Merger Sub") and Carmell Regen Med Corporation, a Delaware corporation ("Legacy Carmell"), ALPA changed its name to "Carmell Therapeutics Corporation" and Merger Sub merged with and into Legacy Carmell. As part of the Business Combination, each share of common stock of Legacy Carmell was exchanged for 0.06154 shares of common stock of Carmell Therapeutics Corporation.
F2: Options are fully vested and exercisable.
F3: Options to purchase 5,318 shares of common stock of Legacy Carmell granted on July 19, 2019, which vest as follows: 25% vested on July 19, 2020, July 19, 2021 and July 19, 2022 and the remaining 25% becomes vested on July 19, 2023.
F4: Options to purchase 119,098 shares of common stock of Legacy Carmell granted on September 23, 2021, which vest as follows: 25% vested on September 23, 2022 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date.
F5: Options to purchase 12,309 shares of common stock of Legacy Carmell granted on July 13, 2023 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date.
F6: Options to purchase 12,309 shares of common stock of Legacy Carmell granted on December 15, 2022, which vest as follows: 25% vesting on December 22, 2023 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date.
F7: As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 14, 2023 Filed Jul 19, 2023 00:39 UTC | Longevity Health Holdings, Inc. CTCX · Entity 8659 | GrantStock Option (right to buy) · Derivative | 12,309 | Not disclosed Strike: $2.60 | Not disclosed |
DisclosureSEC source: 0001062993-23-015060 · form4.xml · derivative · entry 6 Godward Donna · CIK 0001984167 · Chief Quality Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,309 Underlying: Common Stock · 12,309 shares Expires 2032-12-15 F7 · price: As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation. F6 · derivative.exercise_date: Options to purchase 12,309 shares of common stock of Legacy Carmell granted on December 15, 2022, which vest as follows: 25% vesting on December 22, 2023 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date. Read SEC document |
| July 14, 2023 Filed Jul 19, 2023 00:39 UTC | Longevity Health Holdings, Inc. CTCX · Entity 8659 | GrantStock Option (right to buy) · Derivative | 12,309 | Not disclosed Strike: $2.11 | Not disclosed |
DisclosureSEC source: 0001062993-23-015060 · form4.xml · derivative · entry 5 Godward Donna · CIK 0001984167 · Chief Quality Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,309 Underlying: Common Stock · 12,309 shares Expires 2032-07-13 F7 · price: As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation. F5 · derivative.exercise_date: Options to purchase 12,309 shares of common stock of Legacy Carmell granted on July 13, 2023 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date. Read SEC document |
| July 14, 2023 Filed Jul 19, 2023 00:39 UTC | Longevity Health Holdings, Inc. CTCX · Entity 8659 | GrantStock Option (right to buy) · Derivative | 119,098 | Not disclosed Strike: $2.11 | Not disclosed |
DisclosureSEC source: 0001062993-23-015060 · form4.xml · derivative · entry 4 Godward Donna · CIK 0001984167 · Chief Quality Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,098 Underlying: Common Stock · 119,098 shares Expires 2031-09-23 F7 · price: As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation. F4 · derivative.exercise_date: Options to purchase 119,098 shares of common stock of Legacy Carmell granted on September 23, 2021, which vest as follows: 25% vested on September 23, 2022 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date. Read SEC document |
| July 14, 2023 Filed Jul 19, 2023 00:39 UTC | Longevity Health Holdings, Inc. CTCX · Entity 8659 | GrantStock Option (right to buy) · Derivative | 5,318 | Not disclosed Strike: $2.27 | Not disclosed |
DisclosureSEC source: 0001062993-23-015060 · form4.xml · derivative · entry 3 Godward Donna · CIK 0001984167 · Chief Quality Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,318 Underlying: Common Stock · 5,318 shares Expires 2029-07-19 F7 · price: As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation. F3 · derivative.exercise_date: Options to purchase 5,318 shares of common stock of Legacy Carmell granted on July 19, 2019, which vest as follows: 25% vested on July 19, 2020, July 19, 2021 and July 19, 2022 and the remaining 25% becomes vested on July 19, 2023. Read SEC document |
| July 14, 2023 Filed Jul 19, 2023 00:39 UTC | Longevity Health Holdings, Inc. CTCX · Entity 8659 | GrantStock Option (right to buy) · Derivative | 2,090 | Not disclosed Strike: $1.79 | Not disclosed |
DisclosureSEC source: 0001062993-23-015060 · form4.xml · derivative · entry 2 Godward Donna · CIK 0001984167 · Chief Quality Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,090 Underlying: Common Stock · 2,090 shares Expires 2027-06-20 F7 · price: As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| July 14, 2023 Filed Jul 19, 2023 00:39 UTC | Longevity Health Holdings, Inc. CTCX · Entity 8659 | GrantCommon Stock | 37,296 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-23-015060 · form4.xml · nonDerivative · entry 1 Godward Donna · CIK 0001984167 · Chief Quality Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,296 F1 · price: On July 14, 2023, Alpha Healthcare Acquisition Corp. III ("ALPA") consummated a business combination (the "Business Combination") by and among ALPA, Candy Merger Sub, Inc., a Delaware Corporation ("Merger Sub") and Carmell Regen Med Corporation, a Delaware corporation ("Legacy Carmell"), ALPA changed its name to "Carmell Therapeutics Corporation" and Merger Sub merged with and into Legacy Carmell. As part of the Business Combination, each share of common stock of Legacy Carmell was exchanged for 0.06154 shares of common stock of Carmell Therapeutics Corporation. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.